Veterinary Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Veterinary Vaccines Market is segmented by Vaccine Type (Livestock Vaccines and Companion Animal Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Market Snapshot

Veterinary Vaccines Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.1 %
Veterinary Vaccines Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

 The veterinary vaccines market is expected to register a CAGR of about 9.1% during the forecast period.

The market has been impacted majorly by the COVID-19 pandemic. There are a few known COVID-19 infections among pets globally. According to the American Veterinary Medical Association (AVMA), one cat in Belgium tested positive and recovered after nine days. The AVMA conducted two large surveys of practice owners in April and July 2020 to better understand how COVID-19 has affected veterinary practices. They collected over 3,500 responses representing different practice sizes, types, and species. For example, 84% asked clients to wait in vehicles during treatment in April, which impacted the animal vaccines market. All the research and breeding programs have also been put on hold.​

Supply disruption and shortages of veterinary medicines have been observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for COVID-19 medicines. Governments are taking measures to mitigate the supply of medicines. For instance, the impact of the pandemic on the human and veterinary pharmaceutical supply chains in Europe is being closely monitored by the European medicines regulatory network. Although most drug shortages are generally handled at the national level, the EMA (European Medicines Agency) is acting as a central coordinator during the COVID-19 pandemic, assisting the Member States in preventing and minimizing supply disruptions.

Anthrax is one of the most common livestock diseases in the world. According to a report published by WHO (World Health Organization), although national programs have resulted in the containment of anthrax globally, it is still prevalent. The prevalence is primarily due to the lack of experience of the most recent generations of veterinarians in identifying and reporting the disease and the discontinuation of vaccination against the disease.

Livestock diseases are contributing to a set of problems within the livestock production systems, including productivity losses, uncertain food security, and loss of income, adversely affecting human health. Livestock disease management can reduce disease through the vaccination of animals. Foot-and-mouth disease (FMD) is highly contagious among cloven-hoofed animals, like cattle, swine, sheep, goats, and many species of wild animals. Thus, increasing incidences of livestock diseases are the major factors driving the growth of the veterinary vaccines market, as these diseases can be eradicated with the frequent use of vaccines for animals.

Other factors driving the veterinary vaccines market growth are the rising incidence of zoonotic diseases and initiatives taken by government agencies, animal associations, and leading players.

Scope of the Report

Veterinary vaccines are used to immunize domestic, livestock, or wild animals. The veterinary vaccines market is segmented by Vaccine Type (Livestock Vaccines and Companion Animal Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments.

By Vaccine Type
Livestock Vaccines
Bovine Vaccines
Poultry Vaccines
Porcine Vaccines
Other Livestock Vaccines
Companion Animal Vaccines
Canine Vaccines
Feline Vaccines
Equine Vaccines
By Technology
Live Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Other Technologies
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Canine Vaccines Segment is Expected to Show Better Growth in the Forecast Period

Veterinary vaccines are generally used to protect animals from infections like the bluetongue virus, foot-and-mouth disease (FMD), and rabies. Over the forecast period, however, the canine vaccine is expected to increase rapidly because of the increasing number of pet dogs globally. Vaccination has long been a cornerstone of canine medicine, as it is one of the safest and most cost-effective ways to prevent infectious disease.

According to a survey published by American Veterinary Medical Association (AVMA) in November 2021, both dog and cat populations have increased in recent years, as well as the percentages of households owning dogs or cats. There were approximately 83.7 million dogs, 1.46 dogs per household, from 76.8 million in 2016. According to Pet Food Manufacturers Association, as of 2021, 3.2 million households in the UK had acquired a pet since the start of the pandemic. There are now 34 million pets in the UK, including 12 million cats, 12 million dogs, 3.2 million small mammals like guinea pigs and hamsters, 3 million birds, and 1.5 million reptiles. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to enhance during the forecast period due to factors like pet humanization and the rapid adoption of pets in emerging economies. The rising adoption of pet dogs increases the vaccination programs of the companion animals, boosting the canine vaccine segment's growth.

The rapid proliferation of canine vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the segment's strong growth. Moreover, the market is positively affected by evolving vaccine protocols with continuously changing patterns of diseases and the pet population. 

Veterinary Vaccines Market: Total Pet Industry Expenditure in USD million, United States, 2017-2019

North America Dominates the Veterinary Vaccines Market

North America holds the largest market share. Veterinary vaccines in the United States are regulated by the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS). The CVB grants establishment and product licenses to animal health companies to manufacture and sell veterinary biologics.

In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. For instance, in January 2020, Zoetis, a leading animal health company, further expanded its poultry vaccine portfolio by introducing Poulvac Procerta HVT-ND, a vectored recombinant vaccine for protection against Newcastle and Marek’s disease viruses.

Vaccination in companion and wildlife animals for zoonotic diseases greatly impacted reducing the incidence of zoonotic diseases. The rising awareness about the prevention of diseases and technological advancements are also expected to propel the demand for veterinary vaccines in the region.

Veterinary Vaccines Market - Growth Rate By Region

Competitive Landscape

The veterinary vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition due to the rapidly expanding market, fueled by rising concerns over food safety and the increasing adoption of companion animals.


  • In October 2020, Boehringer Ingelheim partnered with Henke-Sass Wolf to develop an innovative intramuscular needle-free vaccine injection tool for pigs around weaning until the end of their nursery.
  • In September 2020, CEVA Sante Animale increased its production capacity for bacterial autogenous vaccines (primarily for pigs and poultry) at its French plant.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Livestock Diseases

      2. 4.2.2 Increasing Pet Adoption Globally

      3. 4.2.3 Initiatives by Government Agencies, Animal Associations, and Leading Players

    3. 4.3 Market Restraints

      1. 4.3.1 High Storage Costs for Vaccines

      2. 4.3.2 Shortage of Veterinarians and Skilled Farm Workers

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Vaccine Type

      1. 5.1.1 Livestock Vaccines

        1. Bovine Vaccines

        2. Poultry Vaccines

        3. Porcine Vaccines

        4. Other Livestock Vaccines

      2. 5.1.2 Companion Animal Vaccines

        1. Canine Vaccines

        2. Feline Vaccines

        3. Equine Vaccines

    2. 5.2 By Technology

      1. 5.2.1 Live Attenuated Vaccines

      2. 5.2.2 Inactivated Vaccines

      3. 5.2.3 Toxoid Vaccines

      4. 5.2.4 Recombinant Vaccines

      5. 5.2.5 Other Technologies

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Zoetis Inc.

      2. 6.1.2 Merck & Co. Inc.

      3. 6.1.3 Virbac

      4. 6.1.4 Hester Biosciences Limited

      5. 6.1.5 Elanco Animal Health

      6. 6.1.6 Boehringer Ingelheim International GmbH

      7. 6.1.7 Ceva Sante Animale

      8. 6.1.8 Phibro Animal Health Corporation

      9. 6.1.9 HIPRA

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Veterinary Vaccines Market market is studied from 2019 - 2027.

The Global Veterinary Vaccines Market is growing at a CAGR of 9.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Zoetis Inc., Merck & Co. Inc., Virbac, Boehringer Ingelheim International GmbH, Elanco Animal Health are the major companies operating in Global Veterinary Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!